Search Results for "ATTRv"
Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.
More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.
For more information about our FDA-approved therapies, please see the Full Prescribing Information:
Vutrisiran: HELIOS-B
Standard response letter on vutrisiran and the HELIOS-B study, a phase 3 study evaluating the efficacy and safety of vutrisiran in patients with the cardiomyopathy of ATTR, including both hATTR and wtATTR.
Standard response letter on vutrisiran and the HELIOS-B study, a phase 3 study evaluating the efficacy and safety of vutrisiran in patients with the cardiomyopathy of ATTR, including both hATTR and wtATTR.
Vutrisiran Treatment in Patients with Transthyretin Amyloidosis with Cardiomyopathy
This asset represents the HELIOS-B primary results, published in the New England Journal of Medicine, in slide deck form.
This asset represents the HELIOS-B primary results, published in the New England Journal of Medicine, in slide deck form.
Vutrisiran: HELIOS-A Study
Standard response letter on vutrisiran and results from the HELIOS-A study evaluating efficacy and safety of vutrisiran in patients with the polyneuropathy of hATTR.
Standard response letter on vutrisiran and results from the HELIOS-A study evaluating efficacy and safety of vutrisiran in patients with the polyneuropathy of hATTR.
Vutrisiran: Dyspnea
Standard response letter on vutrisiran and the adverse event of dyspnea.
Standard response letter on vutrisiran and the adverse event of dyspnea.
